Edition:
India

Xvivo Perfusion AB (XVIVO.ST)

XVIVO.ST on Stockholm Stock Exchange

164.40SEK
16 Sep 2019
Change (% chg)

-1.20kr (-0.72%)
Prev Close
165.60kr
Open
165.20kr
Day's High
165.20kr
Day's Low
164.40kr
Volume
877
Avg. Vol
44,845
52-wk High
204.00kr
52-wk Low
119.80kr

Latest Key Developments (Source: Significant Developments)

XVIVO Perfusion And MyCartis Announce Collaboration
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Xvivo Perfusion AB ::MYCARTIS AND XVIVO PERFUSION AB ANNOUNCE A COLLABORATION.XVIVO AND MYCARTIS ENGAGE TO DEVELOP A FAST DIAGNOSTIC TEST TO ASSESS THE QUALITY OF DONATED ORGANS BEFORE TRANSPLANTATION.  Full Article

Xvivo Perfusion Q1 Adjusted EBITDA Up At SEK 8.8 Mln
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Xvivo Perfusion AB ::STRONG GROWTH IN WARM PERFUSION AND PROGRESS IN THE RESEARCH AND DEVELOPMENT PORTFOLIO.Q1 NET SALES SEK 47.7 MILLION VERSUS SEK 42.5 MILLION YEAR AGO.Q1 ADJ EBITDA SEK 8.8 MLN VS SEK 7.2 MLN YR AGO.  Full Article

Xvivo Perfusion Q3 EBITDA Raises To SEK 5.2 Million
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Xvivo Perfusion AB ::Q3 NET SALES SEK 40.9 MILLION VERSUS SEK 32.3 MILLION YEAR AGO.Q3 EBITDA SEK 5.2 MILLION VERSUS SEK 4.1 MILLION YEAR AGO.  Full Article

Xvivo Perfusion Q2 Net Sales Up At SEK 46.1 Mln
Friday, 20 Jul 2018 

July 20 (Reuters) - Xvivo Perfusion AB ::Q2 NET SALES SEK 46.1 MILLION VERSUS SEK 37.0 MILLION YEAR AGO.Q2 OPERATING INCOME BEFORE DEPRECIATION AND AMORTIZATION (EBITDA) AMOUNTED TO SEK 8.1 (5.7) MILLION.  Full Article

Xvivo Perfusion: Perfadex Plus Approved By The FDA
Monday, 25 Jun 2018 

June 25 (Reuters) - XVIVO PERFUSION AB ::PERFADEX PLUS APPROVED BY THE FDA.  Full Article

Xvivo Q3 EBITDA ex-items at SEK 4.4 million
Friday, 27 Oct 2017 

Oct 27 (Reuters) - XVIVO PERFUSION AB ::Q3 NET SALES SEK ‍32.3​ MILLION VERSUS SEK 31.7 MILLION YEAR AGO.Q3 EBITDA EX-ITEMS SEK ‍4.4​ MILLION VERSUS SEK 5.4 MILLION YEAR AGO.  Full Article

BRIEF-XVIVO Receives Market Approval For STEEN Solution And XPS

* SAID ON SATURDAY RECEIVED MARKET APPROVAL (PMA) FROM FDA FOR STEEN SOLUTION AND XPS